Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AbbVie : Recent Reports from Abbvie Inc. Highlight Findings in Thiazoles (In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:57pm CET

Recent Reports from Abbvie Inc. Highlight Findings in Thiazoles (In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance)

By a News Reporter-Staff News Editor at Drug Week -- A new study on Thiazoles is now available. According to news reporting from North Chicago, Illinois, by NewsRx journalists, research stated, "Ritonavir (RTV) is a weakly basic drug with a pH-dependent solubility. In vitro dissolution and supersatuation behaviors of three Norvir oral products including the tablet, powder, and solution were investigated by two biorelevant dissolution methods with pH alteration: a two-stage dissolution test and a biphasic dissolution-partition test."

Financial support for this research came from AbbVie (see also Thiazoles).

The news correspondents obtained a quote from the research from Abbvie Inc., "The two-stage dissolution test revealed a high degree of supersaturation of RTV from these products accompanied by the occurrence of liquid-liquid phase separation (LLPS) in biorelevant dissolution media. Higher, stable apparent RTV concentrations were observed in the FeSSIF-V2 as compared to those in the FaSSIF-V2, which suggested a food effect with higher exposure in the fed state. This is inconsistent with the evaluation in vivo. The biphasic test revealed significantly lower degrees of supersaturation of RTV in the aqueous media from these dosage forms as compared to results of the two-stage dissolution test. RTV concentrations in octanol at 6 h obtained from the tablet and powder with the use of the biorelevant media are consistent with corresponding in vivo AUC and Cmax under the fasting and moderate fat fed (MFF) states and predict the food effect. The underlying mechanisms responsible for the food effect are also proposed. Fractional partition profiles of RTV obtained in octanol from these three Norvir oral products are in agreement with the corresponding fractional absorption profiles in vivo under both the fasting and MFF states."

According to the news reporters, the research concluded: "This study reveals a complex interplay among the dissolution, precipitation, and partition processes from these formulations that dictate the oral exposure of RTV."

For more information on this research see: In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. Molecular Pharmaceutics, 2017;():. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)

Our news journalists report that additional information may be obtained by contacting H. Xu, NCE-Formulation Sciences, Drug Product Development and Clinical Pharmacology and Pharmacometrics, Abbvie Inc , 1 North Waukegan Road, North Chicago, Illinois 60064, United States. Additional authors for this research include S. Vela, Y. Shi, P. Marroum and P. Gao.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acs.molpharmaceut.7b00552. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Antiinfectives, Antiretrovirals, Antivirals, Illinois, Ritonavir, Thiazoles, North Chicago, United States, Drugs and Therapies, Protease Inhibitors, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBVIE
12/13 ABBVIE : Roche boast stellar PhIII leukemia data for a breakthrough combo with b..
12/12 ABBVIE : IMBRUVICA Pooled Analysis Suggests Benefit in Progression-Free Survival..
12/12 ABBVIE : IMBRUVICA Patient-Reported Outcomes Data Detail Long-Term Improvement i..
12/12 ABBVIE : Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetocl..
12/12 ABBVIE : 36 Saudis graduate from AbbVie’s pharma training program
12/11 ABBVIE : IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatme..
12/09 ABBVIE : IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-..
12/09 ABBVIE : IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term ..
12/07 ABBVIE : IMBRUVICA plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenstrom's M..
12/06 ABBVIE : AbbVies IL-23 blocker shows efficacy in psoriasis trial
More news
News from SeekingAlpha
03:17a BIOTECH ANALYSIS CENTRAL PHARMA NEWS : AbbVie And Roche Stellar Data, Aduro Pull..
12/13 ARGENX : This ASH Winner Has Further Upside Ahead
12/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 13, 2017
12/13 Why Tech Still Looks So Attractive
12/12 Combination of AbbVie's venetoclax and Rituxan successful in late-stage leuke..
Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,67%
P/E ratio 2017 20,99
P/E ratio 2018 16,55
EV / Sales 2017 6,50x
EV / Sales 2018 5,75x
Capitalization 155 B
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 99,9 $
Spread / Average Target 2,6%
EPS Revisions
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE53.23%155 185
MERCK KGAA-10.38%13 853
CONVATEC GROUP-10.13%5 439